Research ExplorerPublicationsCandidate biomarkers in heart failure with reduced and prese...

Candidate biomarkers in heart failure with reduced and preserved ejection fraction

Standard

Candidate biomarkers in heart failure with reduced and preserved ejection fraction. / Sinning, Christoph; Zengin, Elvin; Zeller, Tanja; Schnabel, Renate B; Blankenberg, Stefan; Westermann, Dirk.

In: BIOMARKERS, Vol. 20, No. 4, 2015, p. 258-265.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Sinning, C, Zengin, E, Zeller, T, Schnabel, RB, Blankenberg, S & Westermann, D 2015, 'Candidate biomarkers in heart failure with reduced and preserved ejection fraction', BIOMARKERS, vol. 20, no. 4, pp. 258-265. https://doi.org/10.3109/1354750X.2015.1068856

APA

Sinning, C., Zengin, E., Zeller, T., Schnabel, R. B., Blankenberg, S., & Westermann, D. (2015). Candidate biomarkers in heart failure with reduced and preserved ejection fraction. BIOMARKERS, 20(4), 258-265. https://doi.org/10.3109/1354750X.2015.1068856

Vancouver

Sinning C, Zengin E, Zeller T, Schnabel RB, Blankenberg S, Westermann D. Candidate biomarkers in heart failure with reduced and preserved ejection fraction. BIOMARKERS. 2015;20(4):258-265. https://doi.org/10.3109/1354750X.2015.1068856

Bibtex

@article{ed3b07f988e443318569255bf72667e8,
title = "Candidate biomarkers in heart failure with reduced and preserved ejection fraction",
abstract = "CONTEXT: Patients presenting with heart failure symptoms are categorized into heart failure (HF) with reduced and preserved ejection fraction.OBJECTIVE: Aim is to investigate the additional use of candidate biomarkers to characterize patients with either sub-type of HF.METHODS: Literature search was conducted in the electronic databases MEDLINE and Cochrane Central Register of Controlled Trials from inception through November 2014.RESULTS: The results of 47 diseased and general population cohorts were included.CONCLUSION: Current studies could outline the additional use of candidate biomarkers especially GDF-15, MR-proADM and high-sensitive determined troponin, although major outcome studies are still missing.",
keywords = "Adrenomedullin/analysis, Biomarkers/analysis, Growth Differentiation Factor 15/analysis, Heart Failure/diagnosis, Humans, Peptide Fragments/analysis, Prognosis, Protein Precursors/analysis, Sensitivity and Specificity, Stroke Volume",
author = "Christoph Sinning and Elvin Zengin and Tanja Zeller and Schnabel, {Renate B} and Stefan Blankenberg and Dirk Westermann",
year = "2015",
doi = "10.3109/1354750X.2015.1068856",
language = "English",
volume = "20",
pages = "258--265",
journal = "BIOMARKERS",
issn = "1354-750X",
publisher = "informa healthcare",
number = "4",

}

RIS

TY - JOUR

T1 - Candidate biomarkers in heart failure with reduced and preserved ejection fraction

AU - Sinning, Christoph

AU - Zengin, Elvin

AU - Zeller, Tanja

AU - Schnabel, Renate B

AU - Blankenberg, Stefan

AU - Westermann, Dirk

PY - 2015

Y1 - 2015

N2 - CONTEXT: Patients presenting with heart failure symptoms are categorized into heart failure (HF) with reduced and preserved ejection fraction.OBJECTIVE: Aim is to investigate the additional use of candidate biomarkers to characterize patients with either sub-type of HF.METHODS: Literature search was conducted in the electronic databases MEDLINE and Cochrane Central Register of Controlled Trials from inception through November 2014.RESULTS: The results of 47 diseased and general population cohorts were included.CONCLUSION: Current studies could outline the additional use of candidate biomarkers especially GDF-15, MR-proADM and high-sensitive determined troponin, although major outcome studies are still missing.

AB - CONTEXT: Patients presenting with heart failure symptoms are categorized into heart failure (HF) with reduced and preserved ejection fraction.OBJECTIVE: Aim is to investigate the additional use of candidate biomarkers to characterize patients with either sub-type of HF.METHODS: Literature search was conducted in the electronic databases MEDLINE and Cochrane Central Register of Controlled Trials from inception through November 2014.RESULTS: The results of 47 diseased and general population cohorts were included.CONCLUSION: Current studies could outline the additional use of candidate biomarkers especially GDF-15, MR-proADM and high-sensitive determined troponin, although major outcome studies are still missing.

KW - Adrenomedullin/analysis

KW - Biomarkers/analysis

KW - Growth Differentiation Factor 15/analysis

KW - Heart Failure/diagnosis

KW - Humans

KW - Peptide Fragments/analysis

KW - Prognosis

KW - Protein Precursors/analysis

KW - Sensitivity and Specificity

KW - Stroke Volume

U2 - 10.3109/1354750X.2015.1068856

DO - 10.3109/1354750X.2015.1068856

M3 - SCORING: Review article

C2 - 26301884

VL - 20

SP - 258

EP - 265

JO - BIOMARKERS

JF - BIOMARKERS

SN - 1354-750X

IS - 4

ER -